Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Liabilities (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Total Liabilities for 11 consecutive years, with $422.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 4.34% to $422.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $422.7 million, a 4.34% decrease, with the full-year FY2025 number at $422.7 million, down 4.34% from a year prior.
  • Total Liabilities was $422.7 million for Q4 2025 at Cartesian Therapeutics, up from $408.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $454.6 million in Q3 2024 to a low of $45.7 million in Q3 2023.
  • A 5-year average of $257.2 million and a median of $191.1 million in 2021 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: tumbled 54.19% in 2022, then surged 894.56% in 2024.
  • Cartesian Therapeutics' Total Liabilities stood at $137.4 million in 2021, then plummeted by 47.54% to $72.1 million in 2022, then skyrocketed by 517.11% to $444.7 million in 2023, then decreased by 0.64% to $441.8 million in 2024, then dropped by 4.34% to $422.7 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Total Liabilities are $422.7 million (Q4 2025), $408.5 million (Q3 2025), and $391.4 million (Q2 2025).